BMJ case reports · 2020
Use of remdesivir in the presence of elevated LFTs for the treatment of severe COVID-19 infection.
Клинический случайСтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sabers Andrew J, Williams Amber L, Farley T Michael
Аннотация
An 82-year-old man with an extensive medical history presented to the emergency room with complaints of generalised weakness and cough. He tested positive for COVID-19 10 days prior to presenting to the emergency room. Although his symptoms started a week prior to diagnosis, his weakness increased, warranting emergency response. A comprehensive metabolic panel was drawn from the patient on admission, indicating markedly high liver function tests (LFTs) ≥20 times above the upper limit of normal. On day 1 of admission, the decision was still made to start remdesivir (5-day course) due to decompensated acute respiratory failure as well as dexamethasone. The patient's LFTs significantly improved throughout his hospital stay. The patient made a full recovery and was discharged on day 10 of hospitalisation.
Предметные рубрики MeSH
Adenosine MonophosphateAged, 80 and overAlanineCOVID-19Coronavirus InfectionsDexamethasoneEmergency Service, HospitalHumansLength of StayLiver DiseasesLiver Function TestsMalePandemicsPatient DischargePneumonia, ViralRespiratory InsufficiencySeverity of Illness IndexTreatment OutcomeCOVID-19 Drug Treatment